CurrentCentenePolicy CP.MP.70

Proton and Neutron Beam Therapies

Defines medical necessity and coverage criteria for proton beam therapy (PBT) and neutron beam therapy (NBT) for specified oncologic indications for members/enrollees of Centene-affiliated health plans.

Policy Summary

PayerCentene

PolicyProton and Neutron Beam Therapies

Policy CodePolicy CP.MP.70

Change TypeNo material clinical or coverage changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and supply relevant procedure codes and supporting clinical documentation when requesting PBT or NBT.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~23distinct indications listed as medically necessary for PBT

Salivary glandNBT explicit indication

≤21Pediatric coverage age

77520-77525CPT/HCPCS referenced

11/24Last revision

Coverage Criteria for Proton and Neutron Beam Therapy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

PBT Medically Necessary Indications

Proton beam therapy (PBT) is medically necessary when ANY of the following indications are met:

PBT indications list: A. Ocular tumors, including but not limited to intraocular melanomas; B. Primary spine or spinal cord tumors or metastatic tumors of the spine or spinal cord for which organ-at-risk tolerance may be exceeded with photon treatments; C. Tumors that approach or are located at the base of the skull (eg, chordoma, chondrosarcoma); D. Hepatocellular cancer and intra-hepatic biliary cancers; E. Primary or benign solid tumors or other hematologic malignancies in members/enrollees ≤ 21 years old; F. Tumors/cancers that can be treated with any other type of radiation in members/enrollees with a known genetic mutation/syndrome increasing the risk of cancer; G. Malignant and benign primary CNS tumors, excluding IDH wild-type glioblastoma (GBM); H. Pituitary neoplasms; I. Advanced staged and unresectable head and neck cancers; J. Cancers of the nasopharynx, nasal cavity, paranasal sinuses and other accessory sinuses when normal tissue constraints cannot be met by photon-based therapy; K. Non-metastatic retroperitoneal sarcomas; L. Re-irradiation cases where cumulative critical structure dose would exceed tolerance dose; M. Primary tumors of the mediastinum, including thymic tumors and mediastinal lymphomas, and thoracic sarcomas; N. Non-small cell lung cancer to spare critical structures when photon dose constraints cannot be met; O. Malignant pleural mesothelioma; P. Primary malignant or benign bone tumors; Q. Medically inoperable patients with a diagnosis of cancer typically treated with surgery where dose escalation is required due to inability to receive surgery; R. Primary and metastatic tumors requiring craniospinal irradiation; S. Primary cancers of the esophagus; T. Advanced and unresectable pelvic tumors with significant pelvic and/or peri-aortic nodal disease; U. Members/enrollees with a single kidney or transplanted pelvic kidney where maximal organ avoidance is critical; V. Salivary gland tumors

Each listed indication is independently sufficient per policy.

NBT Medically Necessary Indications

Neutron beam therapy (NBT) is medically necessary for salivary gland tumors when ANY of the following are met:

NBT indications for salivary gland tumors: A. The tumor is considered surgically unresectable, recurrent, or is resected with gross residual disease or positive margins; B. Member/enrollee is medically inoperable.

NBT limited to salivary gland tumors under these conditions.

Not Medically Necessary

Not medically necessary stance

Not medically necessary: All other indications for PBT and NBT not specifically listed in this policy are considered not medically necessary due to insufficient evidence of superiority to other available treatments.

Requests for PBT/NBT for non-listed indications are denial triggers per policy.

Summary of Criteria Revisions and Indications

Policy criteria have been updated over time to add and refine indications for proton beam therapy (PBT) and to clarify inclusion/exclusion of specific cancer types; full criteria appear elsewhere in the policy.

Indication updates summary: Multiple additions and clarifications have been made to the PBT/NBT criteria, including adding intraocular melanomas; clarifying spine/spinal cord indications when organ-at-risk tolerance may be exceeded with photons; inclusion of intra-hepatic biliary cancers; expanding pediatric age cutoff to ≤21 years for certain indications; specifying tumors in patients with cancer-predisposing genetic syndromes; refining CNS tumor language (excluding IDH wild-type GBM); adding mediastinal, thymic, pleural mesothelioma, primary bone tumor, craniospinal irradiation, esophageal, advanced pelvic disease, and single/transplanted pelvic kidney considerations; and adding/clarifying the limited NBT indications for salivary gland tumors. The detailed AND/OR logic and thresholds remain in the main criteria section of the policy.

Summary reflects discrete edits recorded in the revision history.

Neutron Beam Therapy — NCCN position

Neutron Beam Therapy (NBT) clinical stance

NBT clinical note: NBT was historically considered promising for unresectable salivary gland cancer but NCCN no longer recommends NBT as a general solution due to diminishing demand, high long-term toxicity, concerns about randomized trial robustness, and closure of most U.S. centers; the panel recognizes potential value for select patients.

Guidance and rationale referenced to NCCN.

Any indication for proton beam therapy (PBT) or neutron beam therapy (NBT) that is not explicitly listed in this policy is excluded and considered not medically necessary. Requests for therapies outside the enumerated indications may be denied because they lack the required supporting criteria and evidence described in the policy.

The National Comprehensive Cancer Network (NCCN) previously considered neutron beam therapy (NBT) a potential option for unresectable salivary gland cancers but no longer recommends NBT as a general solution because of diminishing demand, significant long‑term toxicity concerns, questions about the robustness of randomized trial data, and the closure of most U.S. treatment centers. NCCN does acknowledge that NBT may retain value for select individual patients.

Coverage under this clinical policy is governed by the terms and conditions of the member’s applicable coverage documents and any state or federal requirements. Where state Medicaid provisions conflict with this clinical policy, state Medicaid rules take precedence. This policy is a guide to medical necessity and does not guarantee payment; administrability is subject to Health Plan-level policies and contract terms.

All indications for PBT and NBT that are not specifically listed as medically necessary in this policy are considered not medically necessary due to insufficient evidence demonstrating superiority over alternative treatments. Requests for non-listed uses will be evaluated against this standard and may be denied.

The inclusion of procedure codes or code descriptions within this clinical policy is for informational purposes only and does not guarantee coverage. Services submitted without documentation that meets the policy’s specified clinical criteria and supporting records may be denied; providers must consult current coding guidance prior to claim submission.

Provider Responsibilities, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for proton and neutron beam therapy delivery codes and related procedures. Providers must submit prior authorization requests with relevant procedure codes (e.g., CPT 77423, 77520, 77522, 77523, 77525; HCPCS S8030) and supporting clinical documentation demonstrating that the indication meets the clinical criteria in this policy. For Medicare members/enrollees, review and comply with applicable NCDs, LCDs, and Medicare Coverage Articles prior to applying criteria. For Medicaid members/enrollees, state Medicaid coverage provisions take precedence if they conflict with this policy.

Prior authorization expected for listed therapy and localization codes (see coding block).
Include clinical rationale, prior treatments, and imaging/operative reports as applicable.

Denial Risk

Denial Risk for Non‑Listed Indications

Requests for proton or neutron beam therapy for indications not enumerated as covered in this policy will be considered not medically necessary and may be denied. Providers should verify that the requested indication aligns with the policy’s listed criteria before submitting authorization requests.

Documentation Required

Coding Does Not Guarantee Coverage

Inclusion or exclusion of specific CPT/HCPCS codes in this policy is for reference only and does not guarantee coverage. Providers must reference current professional coding guidance and the most up-to-date code manuals when billing. Coding alone does not establish medical necessity.

Codes referenced are informational and not all‑inclusive.
Verify coding with current CPT/HCPCS manuals prior to claim submission.

Note

Coverage Conditional on Benefit Terms

Coverage is subject to the member/enrollee’s benefit terms, exclusions, limitations, and any applicable state or federal requirements. This policy is a guide to medical necessity and does not constitute a contract or guarantee of payment. Providers and members/enrollees are bound by the terms of their coverage documents and applicable administrative policies.

Documentation Required

Ocular Tumor Localization Documentation

For ocular (uveal) tumors, document tumor localization method(s) used to define the target for proton beam therapy. Acceptable localization techniques include indirect ophthalmoscopy, transillumination, intraoperative or postoperative ultrasound (performed before proton beam), x‑ray, MRI, CT, funduscopic examination, fluorescein angiography, direct intraoperative tumor measurements, and placement of radio‑opaque fiducial markers (e.g., tantalum rings) when used.

Document which localization techniques were used and include reports/images in the authorization request.
If scleral fiducial placement (e.g., S8030) was performed, include operative note and radiographic correlation.

Note

Surgical‑First Preference

Whenever surgical resection with negative margins is a standard curative option, surgery (including re‑resection to achieve negative margins) remains the preferred definitive treatment. Radiation therapy, including proton or neutron beam therapy, is not a substitute for definitive surgical resection and is generally reserved for unresectable disease, medically inoperable patients, or situations where organ‑sparing dose constraints cannot be met with photon techniques.

Provide documentation of surgical evaluation and reasons surgery is not feasible when claiming non‑surgical candidacy.
Post‑operative RT is generally discouraged except in rare, well‑documented circumstances.

Note

Comparator Therapy Considerations

When photon‑based therapies (e.g., IMRT, 3D conformal RT) can meet normal tissue dose constraints, they are typically preferred over particle therapies. Consider proton or neutron therapy when photon techniques cannot adequately spare nearby critical structures, when dose distribution must be sculpted to avoid exceeding cumulative tolerance in previously irradiated or high‑risk adjacent tissues, or when comparative evidence (including CED enrollment) supports use.

Document why photon therapy is insufficient and include dose‑constraint evaluations or prior radiation records.
ASTRO recommends CED enrollment for certain indications (e.g., prostate cancer) where comparative effectiveness data are limited.

Key Definitions

Proton beam therapy (PBT) — definition and concise description

TermProton beam therapy (PBT)

DefinitionA form of external beam radiation therapy using protons (positively charged subatomic particles) to precisely target a specific tissue mass.

Clinical rationaleProtons deposit most of their energy at a specified depth (Bragg peak), allowing delivery of tumor dose with reduced radiation to surrounding normal tissues compared with conventional photon RT.

Common advantagesMay be preferable for tumors near critical structures, for re-irradiation scenarios, and to reduce late effects in pediatric CNS tumors.

Availability noteAn established, increasingly utilized advanced RT modality with growing pediatric use; guidance and indications referenced from ASTRO and other guidelines.

Neutron beam therapy (NBT) — definition and clinical availability note

TermNeutron beam therapy (NBT)

DefinitionAn external beam radiation modality that utilizes neutrons rather than photons to destroy tumor cells.

Clinical availabilityClinically limited in availability; generation and delivery are more difficult than for photons or protons, so NBT has not gained wide acceptance.

Most studied indicationHistorically most commonly studied for salivary gland tumors, particularly unresectable or recurrent disease.

NBT — alternate definition entry for clarity

Alternate term entryNeutron Beam Therapy (NBT)

Concise definitionRadiation therapy using neutrons, which are heavier than photons and may be more effective for very dense tumors.

Clinical caveatAlthough historically promising for unresectable salivary gland cancer, NCCN no longer recommends routine NBT due to toxicity concerns, limited robust randomized data, and closure of most US centers — it may remain an option for select patients.

Health Plan — definition of the Health Plan term

TermHealth Plan

DefinitionA health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

Policy roleProvides guidance on medical necessity to assist coverage decisions and benefit administration but does not constitute a contract or guarantee of payment.

LimitationsCoverage is subject to all terms, conditions, exclusions and limitations of the member's coverage documents and applicable state and federal requirements.

OpenPayer

Proton and Neutron Beam Therapies

Coverage Criteria for Proton and Neutron Beam Therapy

Procedure and Billing Codes

Provider Responsibilities, Prior Authorization, and Documentation

Background and Context

Key Definitions

77423	High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s).
77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.
S8030	Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy.